Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
Lea BeierShihai LuLionel Riou FrançaSabrina MarlerGregory Y H LipMenno V HuismanChristine TeutschJonathan L HalperinKristina ZintHans-Christoph DienerLaurie BakerChang-Sheng MaMiney PaquetteDorothee B BartelsSergio J DubnerPhilippe LyrerJochen SengesKenneth J RothmanPublished in: PloS one (2022)
Over the past few years, data from phase III of GLORIA-AF show that OACs have become the standard treatment option, with most newly diagnosed AF patients prescribed a NOAC. However, in some regions a remarkable proportion of patients remain undertreated. In comparison with phase II, more patients received NOACs in phase III while the prescription of VKA decreased. VKAs were preferred over NOACs in patients with impaired kidney function.
Keyphrases
- newly diagnosed
- end stage renal disease
- phase iii
- phase ii
- clinical trial
- chronic kidney disease
- ejection fraction
- open label
- atrial fibrillation
- peritoneal dialysis
- prognostic factors
- machine learning
- electronic health record
- quality improvement
- smoking cessation
- deep learning
- big data
- patient reported
- oral anticoagulants